17R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
FILSPARI Commercial GrowthRapid FILSPARI growth across IgA nephropathy and FSGS is strengthening Travere’s commercial base. Record demand, broad prescriber adoption and continued management confidence could support a durable multi-year revenue expansion trajectory.
High-margin Revenue And Improving Cash GenerationThe combination of strong gross profitability, narrowed losses and positive operating cash flow indicates that commercial scale is improving operating leverage. Sustaining this conversion could provide resources to fund development and reduce dependence on external capital.
Expanded Rare-kidney-disease Pipeline And IPPipeline expansion and advancing intellectual-property protection diversify Travere beyond its current product. Civorebrutinib, pegtibatinase and sparsentan method claims could extend the company’s rare-kidney-disease franchise if development and regulatory milestones are achieved.
Bears Say
Very High Leverage And Thin Equity CushionThe sharply weakened capital structure leaves limited protection against commercial or clinical setbacks. High debt relative to equity increases refinancing risk and could constrain investment flexibility, particularly while profitability remains unproven.
Profitability And Free-cash-flow Remain FragileDespite substantial revenue growth, Travere has not yet established durable bottom-line profitability. Modest free cash flow relative to debt and ongoing operating losses reduce the company’s ability to absorb setbacks or finance pipeline investments internally.
Pipeline Expansion Adds Major Financial And Execution ObligationsCivorebrutinib broadens the pipeline but commits substantial future capital and creates development, regulatory and commercialization obligations. These demands could pressure liquidity and shareholder value if the candidate fails to reach or sustain commercial success.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is CHF4.96B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Oct 22, 2026 which is in 58 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Aug 04, 2026. The company reported -CHF0.3 earnings per share for the quarter, missing the consensus estimate of -CHF0.11 by -CHF0.191.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is 0.02.
How many shares outstanding does Travere Therapeutics have?
Currently, no data Available
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -CHF0.3 in its last earnings report, missing expectations of -CHF0.11. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in CH:17R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF60.62 (― Upside)
CHF60.62 (― Upside)
Blogger Sentiment
Neutral
CH:17R Sentiment 56%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
269.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.95%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
17R Company Deck
17R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and a positive growth trajectory: record FILSPARI demand and revenue, an encouraging FSGS launch that outpaced early IgA nephropathy uptake, meaningful pipeline additions (pegtibatinase and civorebrutinib), an IP allowance for IgAN methods, and a reinforced balance sheet following convertible refinancing. Offsetting items include elevated operating expenses, a $40M inducement expense, a $112.5M upfront payment for civorebrutinib (post-quarter), expected higher gross-to-net discounts in H2, and limited disclosure of granular commercial metrics and FSGS-specific IP outcomes. On balance, the strengths and growth drivers substantially outweigh the near-term costs and disclosure gaps reported in the quarter.View all CH:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
――
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―